Real-world effectiveness of maternal genetically inactivated acellular pertussis vaccination in protecting infants under three months of age: a case-control study using concurrent community-based and test-negative controls.

Farooq Phiriyasart, Virasakdi Chongsuvivatwong, Ponlagrit Kumwichar

Abstract read

In one paragraph

Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond.Vaccines · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Farooq PhiriyasartSu-ngai Kolok Hospital, Narathiwat Provincial Public Health Office, Su- ngai Kolok, Narathiwat, Thailand.

Virasakdi ChongsuvivatwongDepartment of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.

Ponlagrit KumwicharDepartment of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand. ponlagrit.k@psu.ac.th.ORCID http://orcid.org/0000-0002-1580-5720

Funding

Thailand Technology and Innovation in Life Sciences National Agency HITAP.F-H/2025/004

6 · The paper itself

Abstract

purposeInfants too young for primary vaccination face the highest risk of severe pertussis and death. While maternal vaccination is the primary protective strategy, the real-world vaccine effectiveness (VE) of acellular pertussis (aP) vaccines in Thailand (including recombinant aP (aP

methodsThis case-control study was conducted in the Narathiwat Province, Thailand, during a pertussis outbreak between September 2023 and October 2024. Participants included 33 symptomatic, polymerase chain reaction (PCR)-confirmed cases, 330 asymptomatic, community-matched controls (for primary comparison), and 41 symptomatic, test-negative controls (for sensitivity simulation). Maternal vaccination with aP vaccine during pregnancy was evaluated against no pertussis vaccination. The main outcome measures were symptomatic PCR-confirmed pertussis. VEs were estimated using a logistic regression model with inverse probability of treatment weighting.

resultsAll vaccinated mothers (98 of 404) received aP

conclusionMaternal aP

Indexed as

aPgenGenetically inactivated pertussis vaccineInfantMaternal immunizationPertussisReal-world evidenceRecombinant pertussis vaccineVaccine effectiveness

Identifiers

PMID42507321

DOI10.1016/j.vaccine.2014.04.022

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.